Source:http://www4.wiwiss.fu-berlin.de/dailymed/resource/drugs/1964
| Predicate | Object |
|---|---|
| rdf:type | |
| rdfs:label |
Plasma-Lyte 148 (Injection, Solution)
|
| dailymed-instance:dosage |
As directed by a
physician. Dosage is dependent upon the age, weight and clinical
condition of the patient as well as laboratory determinations. Parenteral drug
products should be inspected visually for particulate matter and
discoloration prior to administration whenever solution and container
permit. All injections in
VIAFLEX plastic containers are intended for intravenous administration
using sterile equipment. Additives may be incompatible. Complete information is not available. Those additives
known to be incompatible should not be used. Consult with pharmacist, if
available. If, in the informed judgment of the physician, it is deemed
advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing
additives.
|
| dailymed-instance:descripti... |
PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) is a sterile,
nonpyrogenic isotonic solution in a single dose container for
intravenous administration. Each 100 mL contains 526 mg of Sodium
Chloride, USP (NaCl); 502 mg of Sodium Gluconate
(CHNaO); 368 mg of Sodium
Acetate Trihydrate, USP
(CHNaO���3HO); 37 mg
of Potassium Chloride, USP (KCl); and 30 mg of Magnesium Chloride, USP
(MgCl���6HO). It contains no antimicrobial
agents. The pH is adjusted with hydrochloric acid. The pH is 5.5 (4.0 to
8.0). PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) administered
intravenously has value as a source of water, electrolytes, and
calories. One liter has an ionic concentration of 140 mEq sodium, 5 mEq
potassium, 3 mEq magnesium, 98 mEq chloride, 27 mEq acetate, and 23 mEq
gluconate. The osmolarity is 294 mOsmol/L (calc). Normal physiologic
osmolarity range is approximately 280 to 310 mOsmol/L. Administration of
substantially hypertonic solutions may cause vein damage. The caloric
content is 21 kcal/L. The VIAFLEX plastic
container is fabricated from a specially formulated polyvinyl chloride
(PL 146 Plastic). The amount of water that can permeate from inside the
container into the overwrap is insufficient to affect the solution
significantly. Solutions in contact with the plastic container can leach
out certain of its chemical components in very small amounts within the
expiration period, e.g., di-2-ethylhexyl phthalate (DEHP), up to 5 parts
per million. However, the safety of the plastic has been confirmed in
tests in animals according to USP biological tests for plastic
containers as well as by tissue culture toxicity studies.
|
| dailymed-instance:clinicalP... |
PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) has value as a
source of water and electrolytes. It is capable of inducing diuresis
depending on the clinical condition of the patient. PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) produces a
metabolic alkalinizing effect. Acetate and gluconate ions are
metabolized ultimately to carbon dioxide and water, which requires the
consumption of hydrogen cations.
|
| dailymed-instance:activeIng... | |
| dailymed-instance:contraind... |
None
known
|
| dailymed-instance:supply |
PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) in VIAFLEX
plastic containers is available as shown below: Exposure of
pharmaceutical products to heat should be minimized. Avoid excessive
heat. It is recommended the product be stored at room temperature
(25��C); brief exposure up to 40��C does not adversely affect the
product.
|
| dailymed-instance:activeMoi... | |
| dailymed-instance:inactiveI... | |
| dailymed-instance:genericMe... |
Sodium chloride, Sodium Gluconate, Sodium Acetate, Potassium Chloride and Magnesium Chloride
|
| dailymed-instance:fullName |
Plasma-Lyte 148 (Injection, Solution)
|
| dailymed-instance:adverseRe... |
Reactions which may
occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis
or phlebitis extending from the site of injection, extravasation and hypervolemia. If an adverse
reaction does occur, discontinue the infusion, evaluate the patient,
institute appropriate therapeutic countermeasures, and save the
remainder of the fluid for examination if deemed necessary.
|
| dailymed-instance:warning |
PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) should be used
with great care, if at all, in patients with congestive heart failure,
severe renal insufficiency, and in clinical states in which there exists
edema with sodium retention. PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) should be used
with great care, if at all, in patients with hyperkalemia, severe renal
failure, and in conditions in which potassium retention is present. PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) should be used
with great care in patients with metabolic or respiratory alkalosis. The
administration of acetate or gluconate ions should be done with great
care in those conditions in which there is an increased level or an
impaired utilization of these ions, such as severe hepatic
insufficiency. The intravenous
administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes
Injection, Type 1, USP) can cause fluid and/or solute overloading
resulting in dilution of serum electrolyte concentrations,
overhydration, congested states, or pulmonary edema. The risk of
dilutional states is inversely proportional to the electrolyte
concentrations of the injection. The risk of solute overload causing
congested states with peripheral and pulmonary edema is directly
proportional to the electrolyte concentrations of the injection. In patients with
diminished renal function, administration of PLASMA-LYTE 148 Injection (Multiple Electrolytes Injection, Type 1, USP) may result in sodium or
potassium retention.
|
| dailymed-instance:indicatio... |
PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) is indicated as
a source of water and electrolytes or as an alkalinizing agent. PLASMA-LYTE 148
Injection (Multiple Electrolytes Injection, Type 1, USP) is compatible
with blood or blood components. It may be administered prior to or
following the infusion of blood through the same administration set
(i.e., as a priming solution), added to or infused concurrently with
blood components, or used as a diluent in the transfusion of packed
erythrocytes. PLASMA-LYTE 148 Injection and 0.9% Sodium Chloride
Injection, USP are equally compatible with blood or blood
components.
|
| dailymed-instance:represent... | |
| dailymed-instance:routeOfAd... | |
| dailymed-instance:name |
Plasma-Lyte 148
|